Institut Regional Du Cancer De Montpellier

The Institut Regional Du Cancer De Montpellier is a leading oncology research institution conducting advanced clinical trials across a diverse spectrum of malignancies. The center demonstrates particular strength in immunotherapy-based combinations, targeted molecular therapies, and precision medicine approaches, participating in numerous phase II and III international multicenter studies that evaluate novel treatment strategies for both solid tumors and hematological malignancies.

• Breast Cancer: Investigating HER2-targeted therapies for brain metastases, hormone receptor-positive disease with CDK4/6 inhibitors and PI3K inhibitors, triple-negative breast cancer immunotherapy combinations, and novel approaches for managing treatment-related vasomotor symptoms
• Gastrointestinal Cancers: Conducting trials in metastatic colorectal cancer (including MSS/MSI-low and dMMR/MSI subtypes), locally advanced and metastatic rectal cancer with de-escalation strategies, esophageal carcinoma, gastric cancer, pancreatic adenocarcinoma, and anal canal squamous cell carcinoma
• Genitourinary Malignancies: Evaluating checkpoint inhibitors and novel therapeutics in muscle-invasive and metastatic bladder cancer, urothelial carcinoma, and multiple studies in prostate cancer including hormone-sensitive, castration-resistant, and PTEN-deficient disease with PARP inhibitors and AKT inhibitors
• Head and Neck, Lung, and Other Solid Tumors: Researching treatment approaches for squamous cell carcinoma of the head and neck with immunotherapy-radiation combinations, non-small cell lung cancer with adjuvant checkpoint blockade, neuroendocrine tumors with peptide receptor radionuclide therapy (PRRT), diffuse midline gliomas, meningiomas, osteosarcoma, and rare malignancies

The institute participates extensively in perioperative and neoadjuvant treatment strategies, demonstrating expertise in integrating systemic therapies with surgery and radiation. Research focuses include innovative combinations of checkpoint inhibitors with chemotherapy, antibody-drug conjugates, and adaptive treatment approaches. The center also contributes to important studies evaluating quality of life outcomes, treatment de-escalation in selected populations, and biomarker-driven patient selection, positioning itself at the forefront of personalized cancer care and translational oncology research.